iiinova — where your digital self keeps evolving

Reposted by Patrick Forde

Tom Newsom-Davis @tnewsomdavis.bsky.social · 03/03/2025

@patrickforde.bsky.social on developing ADCs Press release that HERTHENA-Lung02 has met its primary end point Could this be an option in (an increasingly crowded) post-Osimertinib field? But ADCs are challenging in NSCLC. Some explanations 👇

052

Reposted by Patrick Forde

Tom Newsom-Davis @tnewsomdavis.bsky.social · 02/03/2025

‼️ 1 day until #BTOG25 ‼️ Things to look forward to #6 @patrickforde.bsky.social updating us on ADCs in NSCLC, in Monday morning therapeutics symposium Recently returned from the USA, now conveniently located at @tcddublin.bsky.social surely solely so he can come to BTOG…

132

Reposted by Patrick Forde

Hidehito HORINOUCHI @hhorinouchi.bsky.social · 10/01/2025

🔥Journal of Clinical Oncology🆙 ✅CheckMate 816: Neoadjuvant Nivo + Ipi vs chemo in Resectable NSCLC 👥Drs. Mark Awad, @patrickforde.bsky.social Nicolas Girard, Jonathan Spicer, Tetsuya Mitsudomi Enriqueta Felip, Mariano Provencio et al. #LCSM @oncoalert.bsky.social ascopubs.org/doi/full/10....

ascopubs.org

Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer

PURPOSENeoadjuvant immune checkpoint blockade with nivolumab plus ipilimumab improves overall survival (OS) in non–small cell lung cancer (NSCLC); however, randomized data for resectable lung cancer a...

042

Patrick Forde @patrickforde.bsky.social · 09/01/2025

Now in @JCO_ASCO led by @DrMarkAwad & @MARIANOPROVENCI exploratory arm neoadj ipi nivo for resectable lung cancer in #CM816 w lots of interesting data! Combo neoadj PD1-CTLA4 blockade without chemo likely not a viable strategy for all comers in NSCLC #lcsm ascopubs.org/doi/10.1200/JC…

070

Patrick Forde @patrickforde.bsky.social · 02/12/2024

Interesting…second line lung cancer trial positive (with caveats), now first line pancreatic cancer. Need to see the paper but TTF is here to stay it seems. Positive Topline Results from Phase 3 PANOVA-3Trial of Tumor Treating Fields for Pancreatic Ca. www.businesswire.com/news/home/20...

businesswire.com

Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer

Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) and Novocure (NASDAQ: NVCR) announced today that the pivotal, Phase 3 PANOVA-3 trial met its primary endpoi

061

Patrick Forde @patrickforde.bsky.social · 26/11/2024

Skyscraper (phase 3 trial of tira plus atezo in PD-L1 high advanced lung cancer) ultimately negative. The rollercoaster is finally back at base, disappointing news and doesn’t bode well for TIGIT as a target. #lcsm www.gene.com/media/press-...

gene.com

Genentech: Press Releases | Monday, Nov 25, 2024

Discover the latest news about our company, our products, our policies, and our people.

0166

Patrick Forde @patrickforde.bsky.social · 21/11/2024

Excellent presentation by Dr. @VirginiaCalvo6 @gecp_org of the recently published Spanish Lung Cancer Group consensus on management of stage III NSCLC. Neoadjuvant chemo-IO has changed the game for this stage of disease. #lcsm

1100

Patrick Forde @patrickforde.bsky.social · 18/11/2024

Anyone come across this before? It seems this trial recruitment company cold emails oncologists and offers them cash to refer pts to other centers for specific clinical trials, seems ethically v murky and perhaps legally so as well?

121